Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial.

Menezes LJ, Pokharel U, Sudenga SL, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schim van der Loeff MF, van der Laan LE, Kipping S, Taylor D, Giuliano AR.

Sex Transm Infect. 2017 May 10. pii: sextrans-2016-053046. doi: 10.1136/sextrans-2016-053046. [Epub ahead of print]

PMID:
28490581
2.

HPV SEROSTATUS PRE- AND POST-VACCINATION IN A RANDOMIZED PHASE II PREPAREDNESS TRIAL AMONG YOUNG WESTERN CAPE, SOUTH AFRICAN WOMEN: THE EVRI TRIAL.

Sudenga SL, Torres BN, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schim Van der Loeff MF, Van der Laan LE, Kipping S, Taylor D, Giuliano AR.

Papillomavirus Res. 2017 Jun;3:50-56. doi: 10.1016/j.pvr.2017.02.001. Epub 2017 Feb 16.

PMID:
28480334
3.

Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens.

Zachor H, Machekano R, Estrella MM, Veldkamp PJ, Zeier MD, Uthman OA, Taljaard JJ, Moosa MR, Nachega JB.

AIDS. 2016 May 15;30(8):1221-8. doi: 10.1097/QAD.0000000000001041.

4.

Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial.

Sudenga SL, Torres BN, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schim Van der Loeff MF, Van der Laan LE, Kipping S, Taylor D, Giuliano AR.

J Infect. 2016 Jan;72(1):60-9. doi: 10.1016/j.jinf.2015.10.001. Epub 2015 Oct 19.

5.

High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial.

Giuliano AR, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, van der Laan LE, Papenfuss M, Engelbrecht S, Schim van der Loeff MF, Sudenga SL, Torres BN, Kipping S, Taylor D.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):227-35. doi: 10.1097/QAI.0000000000000425. Erratum in: J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):e72.

6.

Combination antiretroviral therapy reduces the detection risk of cervical human papilloma virus infection in women living with HIV.

Zeier MD, Botha MH, Engelbrecht S, Machekano RN, Jacobs GB, Isaacs S, van Schalkwyk M, van der Merwe H, Mason D, Nachega JB.

AIDS. 2015 Jan 2;29(1):59-66. doi: 10.1097/QAD.0000000000000512.

PMID:
25387313
7.

The impact of revised PMTCT guidelines: a view from a public sector ARV clinic in Cape Town, South Africa.

Van Schalkwyk M, Andersson MI, Zeier MD, La Grange M, Taljaard JJ, Theron GB.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):234-8. doi: 10.1097/QAI.0b013e31828bb721.

8.

Progression and persistence of low-grade cervical squamous intraepithelial lesions in women living with human immunodeficiency virus.

Zeier MD, Botha MH, van der Merwe FH, Eshun-Wilson I, van Schalkwyk M, la Grange M, Mason D, Louw M, Nachega JB.

J Low Genit Tract Dis. 2012 Jul;16(3):243-50. doi: 10.1097/LGT.0b013e3182403d18.

PMID:
22460273
9.

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE.

Patient Prefer Adherence. 2011;5:357-67. doi: 10.2147/PPA.S22771. Epub 2011 Jul 18.

10.

Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.

van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W.

J Med Virol. 2011 Oct;83(10):1764-9. doi: 10.1002/jmv.22189.

PMID:
21837793
11.

Targeting HIV: past, present and future.

Zeier MD, Nachega JB.

Infect Disord Drug Targets. 2011 Apr;11(2):98-114. Review.

PMID:
21406054
12.

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.

van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, van der Merwe L, Gandhi M, Maartens G.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):333-9. doi: 10.1097/QAI.0b013e31820dc0cc.

13.

Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings.

Eshun-Wilson I, Havers F, Nachega JB, Prozesky HW, Taljaard JJ, Zeier MD, Cotton M, Simon G, Soentjens P.

J Int Assoc Physicians AIDS Care (Chic). 2010 Mar-Apr;9(2):104-8. doi: 10.1177/1545109710361537. Epub 2010 Feb 16.

14.

Combined antiretroviral treatment initiation during hospitalization: outcomes in South African adults.

Eshun-Wilson I, Plas HV, Prozesky HW, Zeier MD, Nachega J, Taljaard JJ.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):105-6. doi: 10.1097/QAI.0b013e3181963cd4. No abstract available.

15.

Symptomatic hyperlactataemia and lactic acidosis in the era of highly active antiretroviral therapy.

Eshun-Wilson I, Soentjens P, Zeier M, Taljaard J.

S Afr Med J. 2005 Dec;95(12):929-30. Review. No abstract available.

16.

African-based CCR5 single-nucleotide polymorphism associated with HIV-1 disease progression.

Hayes VM, Petersen DC, Scriba TJ, Zeier M, Grimwood A, Janse van Rensburg E.

AIDS. 2002 Nov 8;16(16):2229-31. No abstract available.

PMID:
12409748
17.

Novel mutations and SNPs identified in CCR2 using a new comprehensive denaturing gradient gel electrophoresis assay.

Petersen DC, Laten A, Zeier MD, Grimwood A, Rensburg EJ, Hayes VM.

Hum Mutat. 2002 Oct;20(4):253-9.

PMID:
12325020

Supplemental Content

Loading ...
Support Center